

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/28, 9/50		A1	(11) International Publication Number: WO 97/02020 (43) International Publication Date: 23 January 1997 (23.01.97)
(21) International Application Number: PCT/EP96/02892 (22) International Filing Date: 2 July 1996 (02.07.96)		(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/498,386 5 July 1995 (05.07.95) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH [DE/DE]; Byk-Gulden-Strasse 2, D-78467 Konstanz (DE).			
(72) Inventors: DIETRICH, Rango; Im Tiergarten 16, D-78465 Konstanz (DE). SACHS, George; 17986 Boris Drive, Encino, CA 91312 (US). NEY, Hartmut; Peter-Thumb-Strasse 46, D-78464 Konstanz (DE). BENEDIKT, Gerald; Winterbergstrasse 2, D-78465 Konstanz (DE).			
(74) Common Representative: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH; Byk-Gulden-Strasse 2, D-78467 Konstanz (DE).			
(54) Title: ORAL PHARMACEUTICAL COMPOSITION CONTAINING ANTIMICROBIAL ACTIVES AND SUSTAINED RELEASE PANTOPRAZOLE			
(57) Abstract			
An oral pharmaceutical composition of pantoprazole in pellet or tablet form, wherein the pantoprazole is at least partly in slow-release form, is distinguished, on combined administration with an antimicrobially-active ingredient, by an enhanced action of rapid onset against disorders caused by Helicobacter.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

ORAL PHARMACEUTICAL COMPOSITION CONTAINING ANTIMICROBIAL ACTIVES AND SUSTAINED RELEASE PANTOPRAZOLE

Field of the Invention

The present invention relates to oral pharmaceutical compositions in pellet or tablet form for combined use of pantoprazole with an antimicrobially-active ingredient for the treatment of disorders caused by *Helicobacter*.

Background

Pyridin-2-ylmethylsulfinyl-1H-benzimidazoles, as disclosed, for example, in EP-A 0005129, EP-A 0166287 and EP-A 0268956 are becoming increasingly important, because of their H⁺/K⁺ ATPase-inhibiting action, for the therapy of diseases which originate from increased gastric acid secretion. Examples of active ingredients which are already commercially available from this group are omeprazole (INN), lansoprazole (INN) and pantoprazole (INN). These active ingredients are also called irreversible proton pump inhibitors.

Control of the microbe, *Helicobacter pylori*, which is thought to be responsible for certain gastric disorders, by combined use of an antimicrobially-active ingredient which is active against *Helicobacter pylori* and of an agent which reduces gastric acid has been regarded as the method of choice for some time.

EP-A 0519365 proposes (for the active ingredient pantoprazole) a formulation based on the principle of an alkaline core coated with a water-soluble intermediate layer and with an enteric layer, where improved stability is achieved by using polyvinylpyrrolidone and/or hydroxypropylmethylcellulose as

binder for the alkaline core.

EP-A 0342522 discloses a formulation for acid-sensitive benzimidazoles, in which an intermediate layer is located between the alkaline core and the enteric coating and is composed of a film-forming material which has only low solubility in water, such as ethylcellulose and polyvinyl acetate, and of a fine-particle inorganic or organic material which is suspended therein and has low solubility in water, such as magnesium oxide, silicon oxide or sucrose fatty acid esters.

JP-A 59020219 discloses an enteric composition for acid-labile active ingredients which comprises (under the enteric coating) an intermediate layer of a film-forming material, such as hydroxypropylmethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose phthalate with a content of higher fatty acids.

DE-A 3233764 proposes for enteric compositions an intermediate layer which is formed from a water-soluble cellulose ether and a water-soluble mono- or polybasic organic acid, such as citric acid, tartaric acid, and the like.

Combined use of irreversible proton pump inhibitors with antimicrobially-active ingredients does indeed show a good effect against *Helicobacter* *in vitro*. However, the clinical effect achieved with this combined use is disappointing. Of practical inconvenience is the great delay in the onset of action.

Summary of the Invention

The action of an antimicrobially-active ingredient on *Helicobacter* surprisingly is enhanced by administering pantoprazole in slow-release dosage form (extended release form). It must be regarded as particularly surprising that, in addition, administration of the slow-release pantoprazole results in the onset of action taking place significantly faster than on administration in a form without retarding such release. The duration of treatment until *Helicobacter* is eradicated is shortened, saving considerable amounts of antibiotic and acid inhibitor.

The invention thus relates to an oral pharmaceutical composition for treating a disorder caused by *Helicobacter* comprising pantoprazole in combination with at least one antimicrobially-active ingredient, wherein at least part of the pantoprazole is in slow-release form. Further subject-matters are evident from the claims.

Details

In connection with the present invention, pantoprazole is the compound, 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole, its salts and solvates (e.g. hydrates), in particular the sodium salt with one and a half molecules of water of crystallization (pantoprazole Na x 1.5 H₂O).

Examples of suitable antimicrobially-active ingredients (active against *Helicobacter* and, in particular, against *Helicobacter pylori*) are enumerated in European Patent Application EP-A 0282131. These active ingredients include, for example, bismuth salts (such as bismuth subcitrate or bismuth subsalicylate), sulfonamides, nitrofurans (such as nitrofurazone, nitrofurantoin or furazolidone), metronidazole, tinidazole, nimorazole or antibiotics. Examples of antibiotics which may be mentioned in this connection are, arranged according to particular classes of active ingredient: aminoglycosides, such as gentamicin, neomycin, kanamycin, amikacin or streptomycin; macrolides, such as erythromycin, azithromycin, clarithromycin, clindamycin or rifampicin; penicillins, such as penicillin G, penicillin V, ampicillin, mezlocillin or amoxicillin; polypeptides, such as bacitracin or polymyxin; tetracyclines, such as tetracycline, chlorotetracycline, oxytetracycline, minocycline or doxycycline; carbapenems, such as imipenem, loracarbef, meropenem or panipenem; cephalosporins, such as cefalexin, cefoxitin, cefuroxime axetil, cefotaxime, cefpodoxim proxetil, cefaclor, cefadroxil or cephalothin; gyrase inhibitors, such as ciprofloxacin, norfloxacin, ofloxacin or pefloxacin, or other different antibiotics, such as chloramphenicol.

Particularly worthy of mention in this connection

is also the conjoint administration of pantoprazole with a plurality of antimicrobially-active ingredients, for example with a combination of bismuth salt and/or tetracycline with metronidazole, or with the combination of amoxicillin or clarithromycin with metronidazole.

Antimicrobially-active ingredients which may be emphasized are erythromycin, azithromycin, clarithromycin, clindamycin, rifampicin, ampicillin, mezlocillin, amoxicillin, tetracycline, minocycline, doxycycline, imipenem, meropenem, cefalexin, cefuroxime axetil, cefpodoxime proxetil, cefaclor, cefadroxil, ciprofloxacin, norfloxacin, ofloxacin and pefloxacin.

Clarithromycin and amoxicillin may be mentioned as antimicrobially-active ingredients which should be particularly emphasized.

Combined administration means, for the purpose of the present invention, fixed and, in particular, free combinations, i.e. either slow-release pantoprazole and the antimicrobially-active ingredient are present together in one dosage unit, or slow-release pantoprazole and antimicrobially-active ingredient, which are present in separate dosage units, are administered in direct succession or at a relatively large time interval; a relatively large time interval means a time span up to a maximum of 24 hours. For use as separate dosage units, these are preferably made available together in one pack. For example, the two dosage units are packed together in blister packs which are designed with regard to the relative arrangement of the two dosage units with respect to one another, the inscription and/or coloring in a manner known per se so that the times for taking the individual components (dosage regimen) of the two dosage units are evident to a patient.

A dosage unit means, in particular, a medicinal dosage form in which slowing of pantoprazole release is achieved with as few problems as possible. This includes, in particular, tablets, coated tablets or pellets, and microtablets in capsules, with the dosage form advantageously being designed so that the two active-ingredient components (pantoprazole on the one hand and antimicrobially-active ingredient on the other hand) are

released, or made available effectively for the body, in such a way that an optimal active ingredient profile, and thus action profile, is achieved.

It is possible to use (for retarding release) various types and degrees of retardation so that a pantoprazole plasma level, which persists as long as possible and is sufficient for raising pH, is ensured.

The pharmaceutical formulation of the antimicrobially-active ingredient is carried out as is familiar per se to the skilled worker for the individual active ingredient.

Rapid release of part of the pantoprazole and extending release of another part can be achieved, for example, also by layered tablets or multilayer tablets, in which case part of the pantoprazole is present in an outer coating in a form without retarding its release; this is followed by another coating containing the antimicrobially-active ingredient and then the core with the pantoprazole, whose release is extended in a suitable manner.

The details of how to achieve slowing of or extending release are familiar to the skilled worker on the basis of his expert knowledge. The skilled worker is likewise familiar with suitable ancillary substances and vehicles for the required dosage forms (pharmaceutical formulations). Besides solvents, tablet auxiliary substances and other active ingredient excipients it is possible to use, for example, tablet-coating compositions, plasticizers, antioxidants, preservatives, dyes, etc. Where incompatibilities between the active ingredients or between the active ingredients and ancillary substances are expected, suitable separating layers are provided where appropriate (for example in layered or multi-layer tablets).

The dosage of the active ingredients depends greatly on the nature of the antimicrobially-active ingredients used. A typical dosage for pantoprazole can be regarded as being a daily dose of from about 0.01 to about 20, preferably from 0.05 to 5, in particular from 0.1 to 1.5, mg/kg of body weight, where appropriate in the form of a plurality of single doses. Penicillins, such as amoxicillin, are administered in a daily

dose of from about 5 to 40, preferably from 10 to 20, mg/kg of body weight.

Because of a great tendency to decompose in a neutral and, in particular, acidic environment, which also results in highly colored decomposition products, for oral compositions, it is necessary on the one hand to keep pantoprazole in an alkaline environment and, on the other hand, to protect it from exposure to acids. It is generally known to coat tablets or pellets which contain an acid-labile active ingredient with an enteric coating which, after passage through the stomach, rapidly dissolves in the alkaline medium in the intestine. In the case of pantoprazole, which is very acid-labile, it is necessary to process it in the tablet core or in pellets in the form of its alkaline salts, for example as sodium salts, or together with alkaline substances. Since the substances suitable for enteric coatings contain free carboxyl groups, a problem arises when the enteric coating is partly or even completely dissolved from the inside because of the alkaline medium in the interior, and the free carboxyl groups promote decomposition of the active ingredients. It is therefore necessary to provide a sealing intermediate layer (subcoating) between the enteric coating and the alkaline tablet core. EP-A 0244380 proposes to coat cores which contain the active ingredient together with alkaline compounds or as alkaline salt with at least one layer, which is soluble in water or rapidly disintegrates in water, of nonacidic, inert pharmaceutically-acceptable substance before the enteric layer is applied.

The intermediate layer or intermediate layers act as pH-buffering zones in which hydrogen ions, which diffuse in from the outside, are able to react with the hydroxyl ions which diffuse out of the alkaline core. In order to increase the buffer capacity of the intermediate layer, it is proposed to incorporate buffer substance into the intermediate layer(s). It is possible in practice by this method to obtain rather stable compositions. However, relatively thick intermediate layers are required to prevent the unsightly discoloration which occurs even on only slight decomposition. In addition, considerable effort

must be made to avoid traces of moisture during manufacture.

It is a further aim within the scope of the present invention to provide an oral pharmaceutical composition with delayed and controlled release of active ingredients in pellet or tablet form for pantoprazole, which is distinguished by great resistance to decomposition and discoloration of the active ingredient caused by moisture and other effects.

This aim is particularly advantageously achieved by providing at least one release-slowning intermediate layer of water-insoluble film former, which at the same time represents a barrier for mutual interactions between the active ingredient with an alkaline reaction and the enteric coating with an acidic reaction.

In this connection, film formers are regarded as insoluble in water when they cannot be dissolved in water without further additions (organic solvents, detergents, alkalizing substances, etc.).

The invention therefore also relates to an oral pharmaceutical composition in pellet or tablet form for acid-labile irreversible proton pump inhibitors comprising an alkaline pellet or tablet core, at least one release-slowning, release-controlling intermediate layer and an outer enteric layer which is soluble in the small intestine, wherein the intermediate layer for the pharmaceutical composition is formed from a water-insoluble film former, the film former being applied from anhydrous solution or aqueous dispersion.

The slowing of release can be achieved, for example, by a semipermeable membrane, as disclosed in numerous patents (e.g. EP B 0185331).

The details of how to achieve slowing of release are familiar to the skilled worker on the basis of his expert knowledge. The skilled worker is likewise familiar with suitable ancillary substances and vehicles for the required dosage forms (pharmaceutical formulations). Besides solvents, tablet ancillary substances and other active ingredient excipients it is possible to use, for example, tablet-coating compositions, plasticizers, antioxidants, preservatives, dyes, etc. Where

incompatibilities between the active ingredients or between the active ingredients and ancillary substances are expected, suitable separating layers are provided where appropriate.

The oral pharmaceutical compositions according to the invention are distinguished from the prior art by controlled release of active ingredients and increased stability. It is particularly advantageous to keep the intermediate layer (which controls the release of active ingredients) very thin (between 20 and 80, preferably between 40 and 60, μm), which leads to a considerable saving of material and shorter processing times. The insolubility of the intermediate layer in water means that the application of the enteric layer in the form of aqueous suspensions is not critical because there can be no dissolution of the intermediate layer. Furthermore, oral pharmaceutical compositions with a considerably smoother surface are obtained, which not only leads to a better visual appearance but also technically simplifies an imprinting process for tablets.

For a basic reaction of the pellet or tablet core it is mixed (where required increase in pH is not achieved simply by using an active-ingredient salt) with an inorganic base. Mention may be made in this connection of, for example, the pharmacologically-suitable alkali-metal, alkaline-earth-metal or earth-metal salts of weak acids and the pharmacologically-suitable hydroxides and oxides of alkaline-earth and earth metals. Sodium carbonate may be mentioned as a base to be emphasized by way of example.

Besides filler and binder, other ancillary substances, in particular lubricants and nonstick agents, and tablet disintegrants, are used in the manufacture of the tablet cores. A suitable binder is, in particular, polyvinylpyrrolidone in various degrees of polymerization. Examples of lubricants and nonstick agents which may be mentioned are higher fatty acids and their alkali-metal and alkaline-earth-metal salts, such as calcium stearate. Suitable tablet disintegrants are, in particular, chemically inert agents. Tablet disintegrants which may be mentioned as preferred are crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcelluloses

and sodium starch glycolate.

Examples of film-forming polymers which can be used in the water-insoluble release-slowing intermediate layer(s) (to be applied to the pellet or tablet core) include ethylcellulose, polyvinyl acetate, ammonio methacrylate copolymer type A (e.g. Eudragit® RL) and type B (Eudragit® RS) etc. The release rate can be controlled not only by incorporating therein suitable water-soluble pore formers, such as PEG, lactose, mannitol, sorbitol, HPMC, etc., but also by the thickness of the coating layer applied.

The solvents or dispersants used for the release-controlling polymer dispersion are non-aqueous organic solvents, such as alcohols, ketones or halogenated hydrocarbons or mixtures of such solvents.

It is possible in a similar way to use osmotic systems with semipermeable membranes of cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, as described in US-A 3845770, US-A 3916899, US-A 4036227, US-A 4093708, US-A 4096238, US-A 4135514 and US-A 4142526, to control the release of active ingredients. These can be coated with aqueous dispersions of enteric lacquers without changing release rate.

Examples of suitable polymers for the enteric coating are methacrylic acid/methyl methacrylate copolymer or methacrylic acid/ethyl methacrylate copolymer (Eudragit® L) or cellulose derivatives, such as carboxymethylcellulose (CMEC, Duodcel), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HP50, HPSS), hydroxypropylmethylcellulose acetate succinate (HPMCAS) or polyvinyl acetate phthalate, to which it is also possible to add, if desired, plasticizer (such as propylene glycol) and/or other additives and ancillary substances (e.g. buffers, bases, such as, preferably, aluminum hydroxide, or pigments).

The layers are applied in conventional ways using equipment customary for these purposes.

Examples

The following formulation examples explain the invention in detail without restricting it.

Example 1

Tablets:

I. Production of uncoated core:

a)	Pantoprazole Na x 1.5 H ₂ O	45.1 mg
b)	Sodium carbonate	10.0 mg
c)	Mannitol	20.0 mg
d)	HPMC 2910 3 cps	25.0 mg
e)	HPMC 2910 15 cps	4.0 mg
f)	Calcium stearate	2.1 mg
		106.2 mg

a) is mixed with one part of b), c) and d). The remainder of b) and c) is added to the clear aqueous solution of e), and the pH is adjusted to > 10 with b). This solution is used for fluidized bed granulation. The remainder of d) and f) is added to the dried granules, and the granules are compressed in a suitable tabletting machine.

II. Release-slowing layer

g)	Ethylcellulose	9.85 mg
h)	Lactose micronized	2.37 mg
i)	Propylene glycol	0.98 mg
j)	Ammonia 25%	0.80 mg
		14.00 mg

g) is dissolved in 165 ml of isopropanol to prepare solution (A). A fine suspension of h) in 165 ml of isopropanol is prepared using a rotor-stator agitator, and subsequently i) and j) are stirred in using a suitable agitator to prepare suspension (B). The solution (A) and the suspension (B) are combined.

The tablet cores obtained from I are coated to an adequate layer thickness with the suspension obtained above in suitable apparatus.

III. Enteric coating:

l)	Eudragit® L	13.64 mg
m)	Triethyl citrate	1.36 mg
		15.00 mg

1) is diluted with 140 ml of water, and m) is added. The resulting dispersion is screened before processing.

The dispersion from III is sprayed onto the presealed cores obtained from II in suitable equipment.

Example 2

Tablets:

I. Production of the uncoated core:

Production of the cores took place as in Example I point I.

II. Release-slowing layer:

g)	Polyvinyl acetate	9.15 mg
h)	Lactose micronized	2.27 mg
i)	Propylene glycol	0.91 mg
j)	Ammonia 25%	0.80 mg
<hr/>		
		13.13 mg

g) is dissolved in 150 ml of a 1:1 acetone/chloroform mixture to prepare a solution (A).

A fine dispersion of h) in 150 ml of a 1:1 acetone/chloroform mixture is prepared using a rotor-stator agitator, and subsequently i) and j) are stirred in using a suitable agitator to prepare a suspension (B). Solution (A) and suspension (B) are combined.

The tablet cores obtained in I are coated to a sufficient layer thickness with the suspension obtained above in suitable apparatus.

- 12 -

III. Enteric coating:

1)	Eudragit® L	13.46 mg
m)	Triethyl citrate	1.36mg

		15.00 mg

Total weight per enteric film-coated

tablet 183.50 mg

1) is diluted with 135 ml of water, and m) is added.

The dispersion is screened before processing.

The dispersion from III is sprayed onto the presealed cores obtained in II in suitable equipment.

Example 3**Pellets:****I. Starter Pellets**

a)	Sucrose pellets (0.7-0.85 mm)	950.0 g
b)	Hydroxypropylmethylcellulose 2910 (USP)	40.0 g
c)	Propylene glycol	9.9 g
d)	NaOH	0.1 g

a) is sprayed with an aqueous solution of b), c) and d) in a fluidized bed (Wurster method).

II. Active pellets

e)	Pantoprazole Na x 1.5 H	403.0 g
f)	Hydroxypropylmethylcellulose 2910 (USP)	403.0 g
g)	Propylene glycol	201.5 g
h)	NaOH	1.0 g

f), g), h), e) are successively dissolved in 4 liters of purified water and sprayed onto 900 g of the pellets obtained in I in a fluidized bed (Wurster method).

III. Presealed pellets

A release-slowing layer is applied in analogy to the procedure described for tablets in a pan or fluidized bed.

IV. Enteric-coated pellets

The coating is applied in analogy to the procedure described for the tablets in a pan or fluidized bed.

The pellets are subsequently packed into capsules of suitable size (e.g. size 1).

Example 4

Pellets:

I. Active Pellets

c)	Pantoprazole Na x 1.5 H ₂ O	403.0 g
d)	Na carbonate	87.3 g
e)	Microcrystalline cellulose (Avicel PH101)	117.0 g
f)	Na carboxymethylcellulose	18.0 g

c) - f) are premixed dry and subsequently moistened to a paste-like consistency with a solution of Na carbonate and Na carboxymethylcellulose in water in a conventional kneader or high-speed mixer. The resulting composition is then extruded and shaped into pellets by the extruder/rounder

method familiar to the skilled worker. The moistened pellets are dried in suitable equipment (drying oven, fluidized bed, etc.).

III. Release-slowng layer:

The release-slowng layer is applied in analogy to the procedure described for tablets in a pan or fluidized bed.

IV. Enteric-coated pellets

The coating is applied in analogy to the procedure described for tablets in a pan or fluidized bed.

The pellets are subsequently packed into capsules of suitable size (e.g. size 1).

The invention and its advantages are readily understood from the foregoing description. As is apparent, various changes can be made in the products and methods without departing from the spirit and scope of the invention or sacrificing its material advantages. The products and processes hereinbefore described are merely illustrative of a preferred embodiments of the invention.

WHAT IS CLAIMED IS:

1. An oral pharmaceutical composition for treating a disorder caused by *Helicobacter* comprising pantoprazole in combination with at least one antimicrobially-active ingredient, wherein at least part of the pantoprazole is in slow-release form.
2. An oral pharmaceutical composition as claimed in claim 1, wherein the pantoprazole, which is wholly or partly in slow-release form is in fixed combination with at least one antimicrobially-active ingredient in a single dosage unit.
3. An oral pharmaceutical composition as claimed in claim 2, wherein the pantoprazole is in pellet form together with at least one antimicrobially-active ingredient in a capsule as a dosage unit.
4. An oral pharmaceutical composition as claimed in claim 2, wherein the pantoprazole, which is wholly or partly in slow-release form is together with at least one antimicrobially-active ingredient in a multilayer tablet.
5. An oral pharmaceutical composition as claimed in claim 1, wherein the pantoprazole and at least one antimicrobially-active ingredient are in separate dosage units in a single package.

6. An oral pharmaceutical composition as claimed in claim 5, wherein the single package is a blister pack which is designed by the relative arrangement of individual components of the dosage units, by inscription and/or by coloring to communicate the dosage regimen to a patient.

7. An oral pharmaceutical composition as claimed in claim 1, wherein the slow-release form of pantoprazole has an alkaline pellet or tablet core, at least one intermediate layer controlling release of active ingredient, and an outer enteric layer which is soluble in the small intestine.

8. An oral pharmaceutical composition as claimed in claim 7, wherein at least one intermediate layer is formed from a water-insoluble, release-slowng film former.

9. An oral pharmaceutical composition as claimed in claim 8, wherein the film former has been applied from a solution or dispersion.

10. An oral pharmaceutical composition as claimed in claim 8, wherein the intermediate layer contains, as water-insoluble, release-slowng film former, water-insoluble cellulose ether and/or polyvinyl acetate.

11. An oral pharmaceutical composition as claimed in claim 8, wherein the intermediate layer contains, as water-insoluble, release-slowing film former, ethylcellulose, ammonio methacrylate copolymer (Eudragit® RS, Eudragit® RL) or polyvinyl alcohol.

12. An oral pharmaceutical composition as claimed in claim 11, wherein the outer enteric layer, which is soluble in the small intestine, comprises methacrylic acid/methyl methacrylate copolymer or methacrylic acid/ethyl methacrylate copolymer (Eudragit® L).

13. An oral pharmaceutical composition as claimed in claim 7, wherein the outer enteric layer comprises a cellulose-derivative coating.

14. An oral pharmaceutical composition as claimed in claim 13, wherein the cellulose derivative is a member selected from the group consisting of a carboxymethylethylcellulose, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose acetate succinate.

15. An oral pharmaceutical composition as claimed in claim 7, wherein a member selected from the group consisting of a pore former, plasticizer, buffer, base and pigment is additionally present in the intermediate layer.

16. A pharmaceutical as claimed in claim 1, wherein the antimicrobially-active ingredient is a member selected from the group consisting of bismuth subcitrate, bismuth subsalicylate, nitrofurazone, nitrofurantoin, furazolidone, metronidazole, tinidazole, nimorazole, gentamicin, neomycin, kanamycin, amikacin, streptomycin, erythromycin, azithromycin, clarithromycin, clindamycin, rifampicin, penicillin G, penicillin V, ampicillin, mezlocillin, amoxicillin, bacitracin, polymyxin, tetracycline, chlorotetracycline, oxytetracycline, minocycline, doxycycline, imipenem, loracarbef, meropenem, panipenem, cefalexin, cefoxitin, cefuroxime axetil, cefotaxime, cefpodoxime proxetil, cefaclor, cefadroxil, cephalothin, ciprofloxacin, norfloxacin, ofloxacin, pefloxacin and chloramphenicol.

17. The use of pantoprazole in combination with at least one antimicrobially-active ingredient for the preparation of a pharmaceutical composition for the treatment of disorders caused by *Helicobacter* wherein at least part of pantoprazole is in slow-release form.

18. A process for producing an oral pharmaceutical composition in pellet or tablet form for pantoprazole, as active ingredient, or for combined use thereof with at least one antimicrobially-active ingredient for treating a disorder caused by *Helicobacter*, which comprises a) incorporating the active ingredient as an alkaline salt and/or with addition of an alkaline substance in a pellet or tablet core, b) applying thereto at least one release-slowng intermediate layer essentially comprising a water-insoluble, release-slowng acidic film former and c) subsequently applying an outer enteric layer which is soluble in the small intestine.

INTERNATIONAL SEARCH REPORT

International Application No

PLI/EP 96/02892

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/28 A61K9/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,92 03135 (SMITH, KLINE & FRENCH) 5 March 1992 see claims 1-6 see page 2, line 11 - line 20 see page 3, line 29 - line 33 see page 4, line 34 - page 5, line 10 ---	1-3,5,6, 15-17
Y	WO,A,94 24867 (SEPRACOR INC.) 10 November 1994 see claims 1,2 see page 13, line 4 - line 17 see page 14, line 17 - line 23 see example 3 ---	1-3,5,6, 15-17 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

*1 Date of the actual completion of the international search

15 November 1996

Date of mailing of the international search report

28.11.96

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/02892

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 519 365 (BYK GULDEN LOMBERG) 23 December 1992 cited in the application see claims 1,4 see page 2, line 56 - page 3, line 9 see examples 1,2 -----	7

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/EP 96/02892

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9203135	05-03-92	AU-B-	658831	04-05-95
		AU-A-	8424091	17-03-92
		CA-A-	2089748	25-02-92
		EP-A-	0544760	09-06-93
		JP-T-	6503806	28-04-94
-----	-----	-----	-----	-----
WO-A-9424867	10-11-94	AU-A-	6713194	21-11-94
		CA-A-	2161256	10-11-94
		EP-A-	0695123	07-02-96
		JP-T-	8509736	15-10-96
-----	-----	-----	-----	-----
EP-A-519365	23-12-92	AU-A-	1974692	12-01-93
		BG-A-	98286	15-08-94
		CA-A-	2109697	23-12-92
		CN-A-	1067809	13-01-93
		CZ-A-	9302764	13-07-94
		DE-A-	4219390	24-12-92
		WO-A-	9222284	23-12-92
		EP-A-	0589981	06-04-94
		HR-A-	920162	31-08-96
		IL-A-	102096	18-06-96
		JP-T-	6508118	14-09-94
		NO-A-	934648	16-12-93
		NZ-A-	243147	21-12-95
		PL-B-	169951	30-09-96
		SK-A-	128793	08-06-94
-----	-----	-----	-----	-----